

9. Chi CC, Tsai RY, Wang SH. Syringocystadenocarcinoma papilliferum: successfully treated with Mohs micrographic surgery. *Dermatol Surg* 2004; 30: 468–471.
10. Woestenborghs H, Van Eyken P, Dans A. Syringocystadenocarcinoma papilliferum in situ with pagetoid spread: a case report. *Histopathology* 2006; 48: 869–870.
11. Kazakov DV, Calonje E, Zelger B, et al. Sebaceous carcinoma arising in nevus sebaceus of Jadassohn: a clinicopathological study of five cases. *Am J Dermatopathol* 2007; 29: 242–248.
12. Park SH, Shin YM, Shin DH, et al. Syringocystadenocarcinoma papilliferum: a case report. *J Korean Med Sci* 2007; 22: 762–765.
13. Langner C, Ott A. Syringocystadenocarcinoma papilliferum in situ originating from the perianal skin. *APMIS* 2009; 117: 148–150.
14. Hoekzema R, Leenarts MF, Nijhuis EW. Syringocystadenocarcinoma papilliferum in a linear nevus verrucosus. *J Cutan Pathol* 2011; 38: 246–250.
15. Kazakov DV, Requena L, Kutzner H, et al. Morphologic diversity of syringocystadenocarcinoma papilliferum based on a Clinicopathologic study of 6 cases and review of the literature. *Am J Dermatopathol* 2010; 32: 340–347.
16. Leeborg N, Thompson M, Rossmiller S, et al. Diagnostic pitfalls in syringocystadenocarcinoma papilliferum, casereport and review of the literature. *Arch Pathol Lab Med* 2010; 134: 1205–1209.
17. Zhang YH, Wang WL, Rapini RP, et al. Syringocystadenocarcinoma papilliferum with transition to areas of squamous differentiation: a case report and review of the literature. *Am J Dermatopathol* 2012; 34: 428–433.
18. Qureshi HS, Ormsby AH, Lee MW, et al. The diagnostic utility of p63, CK5/6, CK7, and CK20 in distinguishing primary cutaneous adnexal neoplasms from metastatic carcinomas. *J Cutan Pathol* 2004; 31: 145–152.
19. Ivan D, Nash JW, Prieto VG, et al. The use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. *J Cutan Pathol* 2007; 34: 474–480.
20. Liang H, Wu H, Giorgadze TA, et al. Podoplanin is a highly sensitive and specific marker to distinguish primary skin adnexal carcinomas from adenocarcinomas metastatic to skin. *Am J Surg Pathol* 2007; 31: 304–310.
21. Plaza JA, Ortega PF, Stockman DL, et al. Value of p63 and podoplanin (D2-40) immunoreactivity in the distinction between primary cutaneous tumors and adenocarcinomas metastatic to the skin: a clinicopathologic and immunohistochemical study of 79 cases. *J Cutan Pathol* 2010; 37: 403–410.